Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SYNJ2 | O15056 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.37 |
| ▸ | STAT3 | P40763 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Harpagide SCHEMBL30132931 | 1.00 | ALDH1A1 (0.61) | ALDH1A1TSHRKDM4EGLACYP3A4 | |
| Harpagide SCHEMBL1425414 | 1.00 | ALDH1A1 (0.61) | ALDH1A1TSHRKDM4EGLACYP3A4 | |
| SCHEMBL29727271 | 0.84 | ALDH1A1 (0.71) | ALDH1A1TSHRKDM4EGLACYP3A4 | |
| SCHEMBL29208523 | 0.84 | ALDH1A1 (0.71) | ALDH1A1TSHRKDM4EGLACYP3A4 | |
| SCHEMBL29425887 | 0.84 | ALDH1A1 (0.71) | ALDH1A1TSHRKDM4EGLACYP3A4 | |
| SCHEMBL29425781 | 0.83 | ALDH1A1 (0.49) | ALDH1A1TSHRKDM4EGLACYP3A4 | |
| SCHEMBL422972 | 0.81 | ALDH1A1 (0.53) | ALDH1A1TSHRKDM4EGLACYP3A4 | |
| SCHEMBL9057878 | 0.80 | ALDH1A1 (0.51) | ALDH1A1TSHRKDM4EGLACYP3A4 | |
| Antirrhinoside SCHEMBL1424987 | 0.79 | ALDH1A1 (0.51) | ALDH1A1TSHRKDM4EGLACYP3A4 | |
| Antirrhinoside SCHEMBL27233579 | 0.79 | ALDH1A1 (0.51) | ALDH1A1TSHRKDM4EGLACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4255391-B1 | LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION | METRIOPHARM AG (CH) | 2026-05-06 | — | — | EP | claimed |
| EP-4379068-B1 | IRIDOID OR SECO-IRIDOID DERIVATIVES AND THEIR USE IN A TANNING PROCESS | INSTITUT NAT DES SCIENCES APPLIQUEES DE ROUEN (FR) | 2025-06-04 | — | — | EP | claimed |
| WO-2023219526-A1 | MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT | PROKIN MILAN (RS) | 2023-11-16 | — | — | WO | claimed |
| EP-3319965-B1 | NOVEL COMPOUNDS FOR USE IN TREATING OR PREVENTING CANCEROUS DISEASES | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS (GR) | 2022-05-04 | — | — | EP | claimed |
| CN-122056902-A | Pharmaceutical application of harpagoside | 金陵药业股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| EP-4525914-A1 | METHODS OF SELECTIVELY TREATING TENDINOPATHY USING INTERLEUKIN-17 (IL-17) ANTAGONISTS | Novartis AG (CH) | 2025-03-26 | — | — | EP | disclosed |
| US-20240391886-A1 | CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL DISORDERS | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2024-11-28 | — | — | US | disclosed |
| EP-3866773-B1 | CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL DISORDERS | UNIV GEORGIA STATE RES FOUND (US) | 2024-08-28 | — | — | EP | disclosed |
| US-12071415-B2 | Carbon monoxide prodrugs for the treatment of medical disorders | GEORGIA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2024-08-27 | — | — | US | disclosed |
| WO-2023223263-A1 | METHODS OF SELECTIVELY TREATING TENDINOPATHY USING INTERLEUKIN-17 (IL-17) ANTAGONISTS | NOVARTIS AG (CH) | 2023-11-23 | — | — | WO | disclosed |
| WO-2023219526-A1 | MULTITARGET ANTIVIRAL DIETARY SUPPLEMENT | PROKIN MILAN (RS) | 2023-11-16 | — | — | WO | disclosed |
| US-20230338315-A1 | METHOD OF PRODUCING PHARMACEUTICAL COCRYSTALS FOR ADDITIVE MANUFACTURING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2023-10-26 | — | — | US | disclosed |
| US-20230331834-A1 | METHOD OF TREATING TENDINOPATHY USING INTERLEUKIN-17 (IL-17) | NOVARTIS AG (CH) | 2023-10-19 | — | — | US | disclosed |
| EP-4196111-A1 | METHOD OF PRODUCING PHARMACEUTICAL COCRYSTALS FOR ADDITIVE MANUFACTURING | Board of Regents, The University of Texas System (US) | 2023-06-21 | — | — | EP | disclosed |
| WO-2022136344-A1 | MODULATION OF PRDM12 FOR USE IN TREATMENT OF PAIN CONDITIONS | Université Libre de Bruxelles (BE) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022036291-A9 | METHOD OF PRODUCING PHARMACEUTICAL COCRYSTALS FOR ADDITIVE MANUFACTURING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022036291-A1 | METHOD OF PRODUCING PHARMACEUTICAL COCRYSTALS FOR ADDITIVE MANUFACTURING | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391886-A1 | CARBON MONOXIDE PRODRUGS FOR THE TREATMENT OF MEDICAL DISORDERS | PYGL, HMOX2, MB | ALDH1A1 976/4885TSHR 4002/4885KDM4E 2143/4885 |
| US-12071415-B2 | Carbon monoxide prodrugs for the treatment of medical disorders | PYGL, HMOX2, MB | ALDH1A1 976/4885TSHR 4002/4885KDM4E 2143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.